Rohto Pharmaceutical Co.,Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects revised net sales of JPY 236,000 million, operating profit of JPY 33,000 million, profit attributable to owners of parent of JPY 24,000 million and net income per share of JPY 105.20 compared to previously expected net sales of JPY 230,000 million, operating profit of JPY 31,000 million, profit attributable to owners of parent of JPY 22,000 million and net income per share of JPY 96.43.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,805 JPY | -2.65% | -6.34% | -1.34% |
04-04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
04-04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.34% | 4.21B | |
+37.41% | 705B | |
+32.40% | 583B | |
-3.07% | 364B | |
+20.39% | 332B | |
+5.59% | 291B | |
+16.72% | 238B | |
-3.44% | 210B | |
+10.45% | 209B | |
+9.39% | 169B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023